| Literature DB >> 32965785 |
Evanthia Perikleous1, Aggelos Tsalkidis1,2, Andrew Bush3, Emmanouil Paraskakis1,2.
Abstract
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has been emerged as a cardinal public health problem. Children have their own specific clinical features; notably, they seem to be escaping the severe respiratory adverse effects. The international scientific community is rapidly carrying out studies, driving to the need to reassess knowledge of the disease and therapeutic strategies. AIM: To assess the characteristics of COVID-19 infected children worldwide of all ages, from neonates to children and adolescents, and how they differ from their adult counterparts. SEARCH STRATEGY: An electronic search in PubMed was conducted, using combinations of the following keywords: coronavirus, SARS-CoV-2, COVID-19, children. The search included all types of articles written in English between January 1, 2019 until August 15, 2020.Entities:
Keywords: COVID-19; SARS-CoV-2; children; coronavirus
Mesh:
Year: 2020 PMID: 32965785 PMCID: PMC7646267 DOI: 10.1002/ppul.25087
Source DB: PubMed Journal: Pediatr Pulmonol ISSN: 1099-0496
Figure 1Flow chart of the search strategy. COVID‐19, 2019 novel coronavirus disease; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus‐2
Main clinical presentations of pediatric SARS‐CoV‐2 cases from the reviewed literature
| Clinical presentation | Studies | Number of participants ( | Range (%) |
|---|---|---|---|
| Cough | [ | 4845 | 32–75 |
| Fever | [ | 5077 | 35–82 |
| Gastrointestinal symptoms | [ | 4227 | Vomiting: 0–23 |
| Diarrhea: 5–37.5 | |||
| Disease severity | [ | 2527 | Asymptomatic: 4.4–54.5 |
| Mild: 18–58% | |||
| Moderate: 19–56 | |||
| Severe: 0–3.8 | |||
| Critically ill: 0–1.9 |
Abbreviation: SARS‐CoV‐2, severe acute respiratory syndrome coronavirus‐2.
Summary of discrepancy aspects between adults and children COVID‐19 patients
| Feature | Adults | Children | Comment |
|---|---|---|---|
| Infection rate |
The age group of 30–69 years old consists the 77.8% of the total case load |
From a total of 72,314 cases by the Chinese Center for Disease Control and Prevention less than 1% were younger than 10 years old |
Milder symptoms or even asymptomatic carriers among pediatric patients, may be a causation of misdiagnosis or missed diagnosis |
| Incubation period |
5.4 days reported in adults |
The average incubation period is approximately 6.5 days |
The average incubation period in children may be longer than in adults |
| Hospitalization status |
10%–33% were hospitalized, including those admitted to an intensive care unit |
5.7%–20% were hospitalized, and 0.58%–2% were admitted to intensive care unit |
Children had lower hospitalization rates Infants had the highest percentage of hospitalization among pediatric population |
| Fatal outcome |
4% global mortality rate In a depictive Chinese study of 85 fatal cases, most were males, over 50 years old, with chronic diseases; the etiology of death of the majority of cases was multiple organ failure |
Deaths are extremely rare, 24 deaths were published; an infant 10‐month‐old with intussusception, a 14 years old boy with no detail description, 5 cases from a Paris study conducted in a pediatric intensive and high‐dependency care unit, and a case with features of hyperinflammatory shock, 2 cases in a U.S. and Canadian Pediatric Intensive Care Units study both had comorbidities and presented multisystem organ failure, and 1 had gram‐negative sepsis, a case of 17‐year‐old boy previously healthy, who died and autopsy demonstrated eosinophilic myocarditis, a 5‐month‐old infant, from Madrid, with dilated cardiomyopathy and Hurler's disease died, a 7‐year‐old girl with known cardiomyopathy and chronic lung disease, one died from cardiac arrest followed a prolonged period of severe hypoxia, 3 cases from a study in the Suburbs of Paris, 4 cases from a multicenter study involved 82 institutions across 25 European countries, a case with intussusception and sepsis and 2 cases from New York City one with end‐stage osteosarcoma and the second with hemoglobinopathy who suffered from a hypoxic bradycardic arrest |
We are expecting for formal reports regard to children from various countries, especially from Europe Pediatric life‐threatening and fatal cases are seen mostly in patients with underlying diseases; in a study of 48 children, among them 83% had comorbidities, all were admitted to intensive care units and the case fatality rate was 4,2% Alert in children presenting with features similar to typical or atypical Kawasaki disease, and toxic shock syndrome There is a serious, emerging suspicion of myocardial disease complicating COVID‐19 even among children leading in fatal events |
| Common symptoms |
Fever, dry cough, and fatigue; severe cases have been associated with dyspnea and bilateral ground‐glass opacities on CT Rare development of gastrointestinal symptoms |
Fever, dry cough, pneumonia Findings have been similar to adults, but fewer children seem to have manifested severe pneumonia A non‐negligible proportion of children had gastrointestinal symptoms |
At present only 3 cases with anosmia/hyposmia and ageusia/dysgeusia has been reported in children The higher rate of gastrointestinal symptoms in children may be related with elevated expression or different functions of ACE‐2 in their gastrointestinal tract |
| Symptoms on admission |
High fever on admission was linked with ARDS and death |
No symptoms on admission prognosticate outcome |
Fever in children with SARS‐CoV‐2 tends to ease within three days and is not a predictive marker of the final outcome |
| Disease severity |
Particular findings are associated with severe illness, such as high ferritin levels and bilateral lesions on chest CT Most of those who died had co‐existing health conditions |
Most pediatric patients had mild or asymptomatic disease, and had faster recovery, and better prognosis compared with adults A minority of pediatric patients required intensive care support and invasive mechanical ventilation; were suffering from co‐existing conditions |
The majority of children will have much milder illness than is developed in adults and, as well, the asymptomatic infections are not unusual Children have powerful innate immune response and rarely have risk factors, like underlying conditions and obesity |
| Laboratory findings |
Increased liver enzymes, anemia, abnormal coagulation function, hypoalbuminemia, hypouricemia, increased inflammatory markers, and sometimes hyperglycemia |
Increased inflammatory markers were less common in children and lymphocytopenia seemed in a lesser degree White blood cells were oftentimes raised contrary to adults Raised creatine kinase MB isoenzyme (CK‐MB) appears more common in children |
Adults have exhibited very high rates of lymphocytopenia Further studies on the severity of COVID‐19 must use lymphocytes and their interaction with the virus as a focal point CK‐MB heightened levels in children, especially in infants, suggests that heart injury would be more probable to take place |
| Imaging pattern |
The pattern of multifocal peripheral patchy ground glass opacities or mixed consolidation is very suspicious for the disease; and when improved will be absorbed leaving fibrotic stripes Initial imaging may be normal, abnormalities are likely to be observed on CT following 6 days after symptom onset |
Compared with adults, lesions in children are atypical, with more localized ground glass opacities and interlobular septal thickening is scarce The most common finding is unilateral or bilateral sub‐pleural bilateral ground glass opacity Also, asymptomatic children have been reported to demonstrate abnormal CT findings |
Whereas most of the infected children appear with a mild clinical course, plain chest radiography frequently miss out the lesions or the detailed features, indicating that timely thoracic CT imaging is needful Lung changes in infected adults would gradually be absorbed in 2 weeks; on the contrary, most lesions in infected children would probably fully resolve in a week |
| Treatment options |
Many drug categories have been recommended in adults' articles, such as bronchodilators, steroids, antibiotics, antivirals, and diuretics. Usage of teicoplanin, monoclonal and polyclonal antibodies is under examination |
Management is predominantly symptomatic supportive treatment as no specific therapy is currently available In severe cases, intravenous immunoglobulin can be administered |
In a retrospective study of 201 adult patients treatment with methylprednisolone was shown to reduce case‐fatality risk None of the studied antiviral medicines is recommended for treatment of children with COVID‐19 Children with immunocompromised diseases should be isolated |
Abbreviations: ACE‐2, angiotensin converting enzyme II; ARDS, acute respiratory distress syndrome; CK‐MB, creatine kinase MB isoenzyme; COVID‐19, 2019 novel coronavirus disease; CT, computed tomography; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus‐2.